Merck
  • Home
  • Search Results
  • Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation.

Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation.

Oncotarget (2014-04-20)
Samadhi Aparicio-Siegmund, Jan Sommer, Niloufar Monhasery, Ralf Schwanbeck, Eric Keil, David Finkenstädt, Klaus Pfeffer, Stefan Rose-John, Jürgen Scheller, Christoph Garbers
ABSTRACT

The Janus kinase / signal transducer and activator of transcription (Jak/STAT) pathway can be activated by many different cytokines, among them all members of the Interleukin (IL-)6 family. Dysregulation of this pathway, resulting in its constitutive activation, is associated with chronic inflammation and cancer development. In the present study, we show that activity of protein kinase II (CK2), a ubiquitously expressed serine/threonine kinase, is needed for induced activation of STAT1 and STAT3 by IL-6 classic and trans-signaling, IL-11, IL-27, oncostatin M (OSM), leukemia inhibitory factor (LIF) and cardiotrophin-1 (CT-1). Inhibition of CK2 efficiently prevented STAT phosphorylation and inhibited cytokine-dependent cell proliferation in a Jak1-dependent manner. Conversely, forced activation of CK2 alone was not sufficient to induce activation of the Jak/STAT signaling pathway. Inhibition of CK2 in turn inhibited Jak1-dependent STAT activation by oncogenic gp130 mutations. Furthermore, CK2 inhibition diminished the Jak1- and Src kinase-dependent phosphorylation of a constitutively active STAT3 mutant recently described in human large granular lymphocytic leukemia. In conclusion, we characterize CK2 as an essential component of the Jak/STAT pathway. Pharmacologic inhibition of this kinase is therefore a promising strategy to treat human inflammatory diseases and malignancies associated with constitutive activation of the Jak/STAT pathway.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Interleukin-11 human, >97% (SDS-PAGE), recombinant, expressed in baculovirus infected Sf21 cells, lyophilized powder, suitable for cell culture
Sigma-Aldrich
Interleukin-11 from mouse, >97% (SDS-PAGE), recombinant, expressed in E. coli, lyophilized powder
Sigma-Aldrich
Emodin, from Frangula bark, ≥90% (HPLC)
Supelco
Emodin, analytical standard
Sigma-Aldrich
IL-11 human, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Sigma-Aldrich
D-Sorbitol, BioXtra, ≥98%
Sigma-Aldrich
D-Sorbitol, ≥98%
Sigma-Aldrich
D-Sorbitol, BioReagent, suitable for cell culture, suitable for plant cell culture
Sigma-Aldrich
D-Sorbitol, for molecular biology, ≥98%
Supelco
Sorbitol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D-Sorbitol, 99%
Sigma-Aldrich
D-Sorbitol, FCC, FG
Sigma-Aldrich
D-Sorbitol, liquid, tested according to Ph. Eur.
Sigma-Aldrich
Sorbitol F solution, 70 wt. % in H2O, Contains mainly D-sorbitol with lesser amounts of other hydrogenated oligosaccharides
Sigma-Aldrich
D-Sorbitol, BioUltra, ≥99.0% (HPLC)
Sorbitol, European Pharmacopoeia (EP) Reference Standard
USP
Sorbitol, United States Pharmacopeia (USP) Reference Standard